3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
5
Gynecologic
3
Genitourinary
2
Gastrointestinal
2
Sarcoma
1
Head & Neck
1
Dermatologic
1
Classical hematology
1
CNS
1
Conditions
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
9
Gemcitabine
9
Cyclophosphamide
8
Radiotherapy
7
Carboplatin
7
Paclitaxel
6
Cisplatin
6
Trastuzumab
5
Irinotecan
5
Doxorubicin
5
Docetaxel
5
Peripheral Blood Stem Cell Transplantation
4
Filgrastim
4
Capecitabine
4
poly ICLC
3
pazopanib
3
liposomal doxorubicin
3
durvalumab
3
atezolizumab
3
Therapeutics
3
Taxes
3
Surveys and Questionnaires
3
Radiation
3
Polymerase Chain Reaction
3
Oncolytic Virotherapy
3
Letrozole
3
Injections
3
Fulvestrant
3
Fluorodeoxyglucose F18
3
Flow Cytometry
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Genetic Counseling
×
Sarcoma
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled